What Is ONS-5010

ONS-5010 is an investigational ophthalmic formulation of bevacizumab (in the United States) with the potential for redefining the standard of care for retinal diseases such as wet age-related macular degeneration (wet AMD) to address unmet medical needs. Bevacizumab is an anti-vascular endothelial growth factor therapy, or anti-VEGF, a class of medications that slow the growth of abnormal blood vessels that lead to retinal damage in wet AMD.¹

Why Is ONS-5010 Needed?

There is currently no approved ophthalmic formulation of bevacizumab available. Clinicians wishing to treat retinal patients with bevacizumab have used unapproved, repackaged intravenous (IV) bevacizumab provided by compounding pharmacies. These products risk contamination and variable potency, as well as inconsistent availability, which resulted in multiple major supply disruptions in the past several years.²

The regulatory approval of ONS-5010 has the potential to address the need to use unapproved, repackaged IV bevacizumab from compounding pharmacies for the treatment of wet AMD.

Did You Know?

Wet AMD is the leading cause of central visual impairment and blindness in people 65 years of age or older. If left untreated, wet AMD leads to irreversible vision loss in most patients.³

1.75 million people in the United States have wet AMD in 1 or both eyes

Another 7 million individuals are at risk⁴

1. Stahl 2020 2. WHO 2020; Zbacnik 2017; Fanguiero; QSC1995; Singh; ASRS letter, 2024 3. Hobbs 2024; Williams 1998 4. Arch Ophthalmol. 2004;122(4):564-572. doi:10.1001/archopht.122.4.564